DRKS00004593已完成不适用
GAMMA3™INTERNATIONAL MULTICENTRE PROSPECTIVECLINICAL POST-MARKET FOLLOW-UP EVALUATION - Gamma3 F
Stryker Osteosynthesis Clinical Research0 个研究点目标入组 437 人开始时间: 2012年12月12日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 437
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 50 Years 至 one（—）
- 性别
- All
入选标准
- •Male and female patients.
- •Patients of 50 years or older of age at time of surgery.
- •Patients who understand the conditions of the International Multicentre Prospective Clinical Follow-Up Evaluation and are willing and able to participate for the length of the prescribed term of follow-up.
- •Patients with the ability to walk prior to the accident, with or without walking aids.
- •Patients who have given a written consent (signed the Informed Consent form).
排除标准
- •Patients, who as judged by the surgeon, are reasonably unlikely to be compliant with the prescribed post-operative routine and follow-up evaluation schedule,
- •Patients with a physical condition (e.g. severe obesity) or neuromuscular deficit that interferes with the patient’s ability to limit weight bearing or places an extreme load on the implant in the healing period.
- •Patients with other concurrent illnesses which are likely to affect their over all outcome.
- •Patients who have not given a written consent (signed the Informed Consent form).
研究者
相似试验
进行中（未招募）
不适用
A Phase III International Multi-center, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Nitric Oxide Synthase Inhibition with Tilarginine Acetate Injection in Patients with Cardiogenic Shock Complicating Acute Myocardial Infarction,Or, the TRIUMPH Study:Tilarginine Acetate Injection in a Randomized International Study in Unstable AMI Patients / Cardiogenic Shock - TRIUMPH StudyEUCTR2005-000412-27-ATArginox Pharmaceuticals, Inc.700
进行中（未招募）
不适用
A Phase III International Multi-center, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Nitric Oxide Synthase Inhibition with Tilarginine Acetate Injection in Patients with Cardiogenic Shock Complicating Acute Myocardial Infarction,Or, the TRIUMPH Study:Tilarginine Acetate Injection in a Randomized International Study in Unstable AMI Patients / Cardiogenic Shock - TRIUMPH StudyIt is the intent of the proposed study to further evaluate the safety and efficacy of Tilarginine Acetate Injection as a novel, mortality reducing therapeutic drug for patients with cardiogenic shock complicating acute myocardial infarction.EUCTR2005-000412-27-DEArginox Pharmaceuticals, Inc.700
进行中（未招募）
不适用
A Phase III International Multi-center, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Nitric Oxide Synthase Inhibition with Tilarginine Acetate Injection in Patients with Cardiogenic Shock Complicating Acute Myocardial Infarction,Or, the TRIUMPH Study:Tilarginine Acetate Injection in a Randomized International Study in Unstable AMI Patients / Cardiogenic Shock - TRIUMPH StudyIt is the intent of the proposed study to further evaluate the safety and efficacy of Tilarginine Acetate Injection as a novel, mortality reducing therapeutic drug for patients with cardiogenic shock complicating acute myocardial infarction.EUCTR2005-000412-27-BEArginox Pharmaceuticals, Inc.658
进行中（未招募）
不适用
A Phase III International Multi-center, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Nitric Oxide Synthase Inhibition with Tilarginine Acetate Injection in Patients with Cardiogenic Shock Complicating Acute Myocardial Infarction,Or, the TRIUMPH Study:Tilarginine Acetate Injection in a Randomized International Study in Unstable AMI Patients / Cardiogenic Shock - TRIUMPH StudyEUCTR2005-000412-27-CZArginox Pharmaceuticals, Inc.700
进行中（未招募）
不适用
A Phase III International Multi-center, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Nitric Oxide Synthase Inhibition with Tilarginine Acetate Injection in Patients with Cardiogenic Shock Complicating Acute Myocardial Infarction,Or, the TRIUMPH Study:Tilarginine Acetate Injection in a Randomized International Study in Unstable AMI Patients / Cardiogenic Shock - TRIUMPH StudyIt is the intent of the proposed study to further evaluate the safety and efficacy of Tilarginine Acetate Injection as a novel, mortality reducing therapeutic drug for patients with cardiogenic shock complicating acute myocardial infarction.EUCTR2005-000412-27-HUArginox Pharmaceuticals, Inc.658